22 results about "Tumor associated antigen" patented technology

Provided herein are antigen-binding protein constructs (ABPCs) that bind LRRC15, bispecific ABPCs that bind both LRRC15 and an additional Tumor-Associated Antigen (TAA), conjugation linkers, and methods of production and uses therefor.

This invention discloses a multifunctional engineered NK cell, its construction method, and its applications. This NK cell co-expresses a membrane-bound targeted cytokine complex and a secretory bispecific nanobody via a single-carrier system. The membrane-bound complex uses an anti-PD-L1 single-domain antibody to directionally anchor IL-15 / IL-21 to the cell membrane surface and utilizes synaptic recruitment to achieve high-level enrichment of cytokine signals at the immune synapse, enabling precise paracrine secretion of cytokine signals. The secretory bispecific antibody mediates specific cytotoxicity by transdirectionally linking the NK cell activation receptor NKp46 with the tumor-associated antigen B7-H3. Experiments have demonstrated that the engineered NK cells constructed in this invention significantly enhance the killing efficacy against PD-L1 or B7-H3 positive tumor cells while maintaining a high P2A cleavage rate, and the synergistic index shows a significant synergistic effect. This invention effectively overcomes the technical shortcomings of traditional NK cell therapy, such as systemic cytokine toxicity and tumor antigen escape, providing a novel strategy for immunotherapy of solid tumors.

The invention provides a multispecific binding molecule, and relates to the technical field of biology. The multispecific binding molecule can bind a plurality of tumor associated antigens at the same time, and the tumor treatment effect can be improved.

The present disclosure provides a vaccine against cancers that express MHC-II. That includes hormone positive breast cancers and some prostate cancers and melanoma. It is possible, based on a genomic test of the individual, to either (1) design a personal vaccine consisting of a polytope based on epitopes from the TAA that in most cases display on MHC-II and not on MHC-I, or (2) select previously manufactured sequences based on epitopes from the TAA as constituents of the vaccine, such that the cancer after vaccination will reveal itself to the immune system and get eradicated while there are little side effects in that the vaccine will not make the immune system harm the healthy tissue.

The present disclosure relates to methods of treating or inhibiting the growth of a tumor, wherein the methods include selecting a subject with cancer and administering to the subject in need thereof a therapeutically effective amount of a cancer vaccine (e.g., mRNA vaccine against a tumor) in combination with a bispecific antigen-binding molecule comprising a first antigen-binding domain that binds specifically CD28 and a second antigen-binding domain that binds specifically to a tumor-associated antigen (TAA). The combination therapy demonstrates increased anti-tumor efficacy, increased duration of tumor control and / or increased overall survival, as compared to a subject administered the cancer vaccine as monotherapy.

The application provides a kind of bispecific antibody and its preparation and application, the bispecific antibody includes two chains: from N end to C end in order: VH1 (or VL1), L1, VH2, CH1, the first polypeptide chain of Fc, and from N end to C end in order: VL1 (or VH1), L2, VL2, CL, second polypeptide chain.It is realized tumor selective accumulation by being located in the N end of double antibody structure of the binding domain targeted to tumor associated antigen (TAA), and its shield is located in the inside immune checkpoint antibody fragment to the binding activity of immune checkpoint to reduce systemic activity.

The present invention relates to a binding protein and use thereof, the binding protein comprising a first binding domain, a second binding domain, and a third binding domain, wherein: the first binding domain is a domain that specifically binds to a tumor-associated antigen (TAA); the second binding domain is both an auxiliary domain that specifically binds to the TAA and a domain that repolarizes the tumor microenvironment (TME) from tolerogenic to pro-inflammatory and, at the same time, specifically binds to an immune checkpoint protein, for in situ T cell priming; and the third binding domain is an effector molecule for inducing T cell response activation and in situ T cell priming in the TME.

The present application relates to a bi-functional therapeutic for treating cancer that includes a targeting component which targets a tumor-associated antigen and an enzyme which, when delivered to a tumor by said targeting component, converts the tumor phenotype to that of an incompatible allograft or xenograft. The enzyme is coupled to the targeting component. Also disclosed is a method for treating cancer comprising administering the bi-functional therapeutic.

This invention relates to multispecific antibodies comprising a first Fv fragment targeting CD3, a second Fv fragment targeting an immune receptor such as CD137 or PD-L1, and one or more binding moieties targeting tumor-associated antigens. The therapeutic use of these multispecific antibodies in cancer therapy is also provided herein.

Disclosed are multispecific antibodies comprising an antibody or antigen binding fragment targeting CD3, an antibody or antigen binding fragment targeting 4-1BB, and another antibody or antigen binding fragment specific for a tumor associated antigen, such as WT1 presented by HLA-A2, expressed in a variety of tumor cancers. Such multispecific antibodies have enhanced efficacy and reduced toxicity, and are thus particularly suitable for treating diseases such as cancer.

Provided in the present disclosure is a multispecific binding molecule, relating to the technical field of biology. The multispecific binding molecule can simultaneously bind to a plurality of tumor-associated antigens, and can improve the effect of tumor treatment.

The present application relates to the technical field of mRNA vaccine, in particular to a multi-antigen tandem mRNA lung cancer vaccine and its application in the preparation of an anti-tumor drug, comprising an mRNA molecule and a lipid nanoparticle encapsulating the mRNA, the mRNA sequentially comprises a cap structure, a 5' untranslated region, an open reading frame, a 3' untranslated region and a polyA tail from 5' end to 3' end, the open reading frame encodes a fusion antigen protein, which sequentially comprises a signal peptide, a lung cancer shared mutant antigen module, a tumor associated antigen module and a MHC-I directed transport domain, each antigen fragment is connected by an AAY connecting peptide, and the lipid nanoparticle is composed of ionized lipids, cholesterol, auxiliary phospholipids and PEG-lipids. The present application takes into account antigen specificity and coverage, can efficiently release antigen epitopes, improve antigen presentation efficiency, strongly activate specific anti-tumor immunity, adapt a stable delivery system, and has a good application prospect in lung cancer treatment.

The present application relates to a kind of glutathione-responsive exosome biomimetic dendrimer nanogel vaccine and its preparation method and application.The vaccine is loaded with 5-Aza, coated with tumor cell Ex and modified R837 in turn to prepare dendrimer nanogel as carrier.The vaccine realizes precise drug delivery of tumor by virtue of the homologous targeting characteristics of Ex, and can target drug release in response to the high glutathione characteristics of tumor microenvironment.5-Aza exerts epigenetic therapy effect through DNA demethylation, while inducing pyroptosis type ICD of tumor cells.R837 immunoadjuvant can synergize with tumor-associated antigens carried by Ex to promote the maturation of dendritic cells, promote the polarization of M2 type tumor-associated macrophages to M1 type, and reverse the tumor immunosuppressive microenvironment.The present application combines epigenetic therapy and immunotherapy, providing a new strategy for the clinical treatment of pancreatic cancer, and has wide clinical application prospect.

To provide improved redirected targeted T-cell cytotoxicity approaches.SOLUTION: The present disclosure provides trispecific binding molecules that specifically bind to CD2, CD3 and a tumor-associated antigen, conjugates comprising the trispecific binding molecules, and pharmaceutical compositions comprising the trispecific binding molecules and the conjugates. The disclosure further provides methods of using the trispecific binding molecules to treat cancers that express the tumor-associated antigens. The disclosure yet further provides recombinant host cells engineered to express the trispecific binding molecules and methods of producing the trispecific binding molecules by culturing the host cells under conditions in which the trispecific binding molecules are expressed.SELECTED DRAWING: None

Provided herein are recombinant poxviruses comprising heterologous or native nucleic acids specifying excess double-stranded RNA (dsRNA) early in infection, which may further comprise heterologous nucleic acids encoding one or more costimulatory molecules, and / or heterologous nucleic acids encoding one or more infectious disease-associated antigens or tumor-associated antigens, as well as pharmaceutical compositions comprising such recombinant poxviruses and methods and uses thereof. The recombinant poxviruses provided herein enhance innate and adaptive immune activation in subjects compared to identical recombinant poxviruses lacking heterologous or native transcription units specifying excess early dsRNA.

The application discloses a long-acting multifunctional antibody as well as a construction method and application thereof, and belongs to the technical field of biotechnology. The multifunctional antibody molecule takes a Fab fragment of a monoclonal antibody as a first domain, and connects a second domain, a third domain and a fourth domain through a connecting peptide on the basis of the first domain, wherein the second domain and the third domain are respectively a binding domain targeting a tumor-related antigen or a T cell costimulatory domain, and the fourth domain is an albumin binding domain. The application realizes the prolongation of the half-life of the antibody in the body while maintaining the multi-target function activity through a modular structure design, thereby reducing the administration frequency and improving the treatment effect. The multifunctional antibody can be used for preparing a medicine for treating tumors.

This invention relates to γδT cell culture technology, specifically a method and application for activating γδT cells using circulating tumor cells (CTCs) or their derivatives. The method includes obtaining donor-derived γδT cells; obtaining CTCs or their derivatives from cancer patients; and co-culturing the γδT cells with the CTCs or their derivatives in an in vitro co-culture system, thereby activating the γδT cells under the stimulation of the CTCs or their derivatives to obtain CTC-γδT cells. This invention utilizes patient-derived circulating tumor cells as the activation stimulus for γδT cells, enabling the resulting γδT cells to recognize tumor-associated antigens and personalized neoantigens, overcoming tumor heterogeneity and antigen escape problems.

This description relates to anti-CLEC5A antibodies (C-type lectin domain family 5 member A) and antigen-binding fragments thereof. This description relates to an antibody or antigen-binding fragment thereof, comprising a first antigen-binding domain that binds specifically to a tumor-associated antigen (TAA), a second antigen-binding domain that binds specifically to CLEC5A, and an Fc region. The present invention also relates to an antibody or antigen-binding fragment thereof, comprising a second antigen-binding domain that binds specifically to an autoimmune disease target and CLEC5A, and an Fc region.

This invention provides a spatial identifying pair of endogenous antibody heavy-light chains (SIPEAC) and a method for assessing antibody heavy-light chain pairing based on spatial transcriptomics. The identification platform developed in this invention, based on the in situ acquisition of the full-length sequences of antibody heavy and light chains from tissues, can accurately resolve the natural pairing relationships between antibody heavy and light chains. This provides technical support for high-throughput cloning and expression of tissue-derived monoclonal antibodies, systematic recognition of tumor-associated antigens (TAAs), and the development of antibody or cell-engineered immunotherapy strategies, significantly promoting the systematic identification and downstream applications of TAAs.

Provided herein are therapeutic agents, pharmaceutical compositions, and methods comprising an IgA constant region. The compositions and methods described herein facilitate binding of an antibody construct comprising an IgA constant domain to CD47 and an antigen for instance a tumor related antigen such as CD20 or CD19.

Provided herein are antigen-binding protein constructs (ABPCs) that bind LRRC15, bispecific ABPCs that bind both LRRC15 and an additional Tumor-Associated Antigen (TAA), conjugation linkers, and methods of production and uses therefor..

The application discloses a reduction-responsive nanoparticle-armed chimeric antigen receptor T cell and a preparation method and application thereof, and belongs to the technical field of antigen receptor T cells. The chimeric antigen receptor T cell comprises a T cell expressing a chimeric antigen receptor for a tumor-related antigen; and a plurality of reduction-responsive hybrid nanoparticles fixed on the outer surface of the T cell. The application utilizes the tumor targeting property of the CAR T cell itself, precisely enriches a drug delivery system at a tumor site, and realizes site-specific and controllable release of the drug by depending on the reduction microenvironment generated on the surface of the CAR T cell after activation, so that the toxic and side effects of systemic drug administration are greatly reduced.